---
title: "The company's assertion that depth of IgG suppression matters in FcRn indications was clinically… — 하나증권 제약/바이오 김선아 — DecisionGateway"
description: "statement by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d887-39c7-7eca-91fc-2d469a07053a"
meta:
  "og:description": "statement by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "The company's assertion that depth of IgG suppression matters in FcRn indications was clinically… — 하나증권 제약/바이오 김선아 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **The company's assertion that depth of IgG suppression matters in FcRn indications was clinically demonstrated.**

A statement by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *FcRn 적응증에서 IgG 억제의 깊이가 중요하다는 회사의 주장을 임상적으로 입증한 것*

hanaresearchPublished 2026-11-10 [ Read source](https://t.me/hanaresearch/20929)

## **Discussion**

## **Related claims**

[**Rheumatoid arthritis may be a disease that requires suppression of pathogenic autoantibodies to a very deep level to confirm efficacy, consistent with J&J's nifocalimab failing in rheumatoid arthritis with a low ACPA antibody reduction rate.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db67-7dd6-a7fd-f6d5cc9c3485) [**Growth defied RBI predictions.**THnewsupdates · statement](https://dgw.tmarket.io/claims/01a1c6ad-cc4e-71ce-aaae-5bbf00184571) [**Whether approval for preparatory establishment is granted or the application is rejected, the FSC will issue a press release to explain publicly in addition to replying to the applicant.**劉純斌 · commitment](https://dgw.tmarket.io/claims/01a1cf3a-d02e-7ccc-96e9-5961077e6dc4) [**Investors awaited fresh signals from the Federal Reserve on its policy outlook.**LiveMint · statement](https://dgw.tmarket.io/claims/01a1c6d1-366c-7a0c-a06b-61b381bc142e) [**Following the halt of cutaneous lupus erythematosus development, a possibility of halting Sjögren's syndrome after completing phase 2 was mentioned; the pipeline value damage from indication discontinuations is judged limited.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db85-771a-af79-4f315d914e06) [**Roivant CEO Matt Gline said on the conference call that they learned exciting, highly competitively valuable things and will say almost nothing about antibody reduction, but have a good amount of confidence going into phase 3.**Matt Gline · statement](https://dgw.tmarket.io/claims/01a1d950-db72-700c-89bd-7101e1154dde)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39c7-7eca-91fc-2d469a07053a#webpage","@type":"WebPage","description":"statement by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation.","name":"The company's assertion that depth of IgG suppression matters in FcRn indications was clinically… — 하나증권 제약/바이오 김선아 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d887-39c7-7eca-91fc-2d469a07053a","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d887-39c7-7eca-91fc-2d469a07053a#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d887-39c7-7eca-91fc-2d469a07053a"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39c7-7eca-91fc-2d469a07053a#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"The company's assertion that depth of IgG suppression…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39c7-7eca-91fc-2d469a07053a#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/hanaresearch/20929","text":"FcRn 적응증에서 IgG 억제의 깊이가 중요하다는 회사의 주장을 임상적으로 입증한 것","url":"/claims/01a1d887-39c7-7eca-91fc-2d469a07053a"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.